Pindobind | CAS#106469-52-7

MedKoo Cat#: 534906 | Name: Pindobind

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pindobind is a bioactive chemical.

Chemical Structure

Pindobind

CAS#106469-52-7

Theoretical Analysis

MedKoo Cat#: 534906

Name: Pindobind

CAS#: 106469-52-7

Chemical Formula: C23H34BrN3O3

Exact Mass: 479.1784

Molecular Weight: 480.45

Elemental Analysis: C, 57.50; H, 7.13; Br, 16.63; N, 8.75; O, 9.99

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Pindobind

IUPAC/Chemical Name

Acetamide, 2-bromo-N-(4-(1-((2-hydroxy-3-(1H-indol-4-yloxy)propyl)amino)-1-methylethyl)-1-methylcyclohexyl)-

InChi Key

XSAGAZCYTLNCEN-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H34BrN3O3/c1-22(2,16-7-10-23(3,11-8-16)27-21(29)13-24)26-14-17(28)15-30-20-6-4-5-19-18(20)9-12-25-19/h4-6,9,12,16-17,25-26,28H,7-8,10-11,13-15H2,1-3H3,(H,27,29)

SMILES Code

O=C(NC1(C)CCC(C(C)(NCC(O)COC2=CC=CC3=C2C=CN3)C)CC1)CBr

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 480.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Frank MG, Johnson DR, Hendricks SE, Frank JL. Monocyte 5-HT1A receptors mediate pindobind suppression of natural killer cell activity: modulation by catalase. Int Immunopharmacol. 2001 Feb;1(2):247-53. doi: 10.1016/s1567-5769(00)00015-1. PMID: 11360926. 2: Cao BJ, Rodgers RJ. Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. I. Pindolol enantiomers and pindobind 5-HT1A. Pharmacol Biochem Behav. 1997 Oct;58(2):583-91. doi: 10.1016/s0091-3057(97)00280-3. PMID: 9300623. 3: Risinger FO, Boyce JM. 5-HT1A receptor blockade and the motivational profile of ethanol. Life Sci. 2002 Jun 28;71(6):707-15. doi: 10.1016/s0024-3205(02)01728-9. PMID: 12072158. 4: Bell R, Hobson H. Effects of pindobind 5-hydroxytryptamine1A (5-HT1A), a novel and potent 5-HT1A antagonist, on social and agonistic behaviour in male albino mice. Pharmacol Biochem Behav. 1993 Sep;46(1):67-72. doi: 10.1016/0091-3057(93)90318-n. PMID: 8255924. 5: Griebel G, Rodgers RJ, Perrault G, Sanger DJ. The effects of compounds varying in selectivity as 5-HT(1A) receptor antagonists in three rat models of anxiety. Neuropharmacology. 2000 Jul 24;39(10):1848-57. doi: 10.1016/s0028-3908(00)00074-5. PMID: 10884565. 6: Appert-Collin A, Duong FH, Passilly DeGrace P, Bennasroune A, Poindron P, Warter JM, Gies JP. Xaliproden (SR57746A) induces 5-HT1A receptor-mediated MAP kinase activation in PC12 cells. Int J Immunopathol Pharmacol. 2005 Apr- Jun;18(2):233-44. doi: 10.1177/039463200501800206. PMID: 15888246. 7: Chang FC, Tsai HY, Yu MC, Yi PL, Lin JG. The central serotonergic system mediates the analgesic effect of electroacupuncture on ZUSANLI (ST36) acupoints. J Biomed Sci. 2004 Mar-Apr;11(2):179-85. doi: 10.1007/BF02256561. PMID: 14966368. 8: Griebel G, Rodgers RJ, Perrault G, Sanger DJ. Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists. Psychopharmacology (Berl). 1999 May;144(2):121-30. doi: 10.1007/s002130050984. PMID: 10394992. 9: Horinouchi T, Koike K. Further characterization of beta3-adrenoceptors in the guinea pig gastric fundus: stereoselectivity, beta-adrenoceptor alkylation, and structure-activity relationship. Can J Physiol Pharmacol. 2001 Dec;79(12):985-95. PMID: 11824942. 10: Kuo CC, Tsai HY, Lin JG, Su HL, Chen YF. Spinal Serotonergic and Opioid Receptors Are Involved in Electroacupuncture-Induced Antinociception at Different Frequencies on ZuSanLi (ST 36) Acupoint. Evid Based Complement Alternat Med. 2013;2013:291972. doi: 10.1155/2013/291972. Epub 2013 Mar 28. PMID: 23606876; PMCID: PMC3625581. 11: Fenrick R, Pou C, Beliveau M, Fargin A. The human 5-hydroxytryptamine 1A receptor differentially modulates phospholipase C and adenylyl cyclase activities. Gen Pharmacol. 1996 Mar;27(2):263-8. doi: 10.1016/0306-3623(95)02028-4. PMID: 8919640. 12: Lezama EJ, Konkar AA, Salazar-Bookaman MM, Miller DD, Feller DR. Pharmacological study of atypical beta-adrenoceptors in rat esophageal smooth muscle. Eur J Pharmacol. 1996 Jul 11;308(1):69-80. doi: 10.1016/0014-2999(96)00236-1. PMID: 8836634. 13: Horinouchi T, Koike K. Functional properties of atypical beta-adrenoceptors on the guinea pig duodenum. Eur J Pharmacol. 2001 Mar 23;416(1-2):153-63. doi: 10.1016/s0014-2999(01)00877-9. PMID: 11282125. 14: Miyazato H, Skinner RD, Crews T, Williams K, Garcia-Rill E. Serotonergic modulation of the P13 midlatency auditory evoked potential in the rat. Brain Res Bull. 2000 Mar 15;51(5):387-91. doi: 10.1016/s0361-9230(99)00257-9. PMID: 10715558. 15: Marazziti D, Palego L, Giromella A, Mazzoni MR, Borsini F, Mayer N, Naccarato AG, Lucacchini A, Cassano GB. Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain. Int J Neuropsychopharmacol. 2002 Jun;5(2):131-40. doi: 10.1017/S1461145702002869. PMID: 12135537. 16: Zhong H, Minneman KP. Coexisting beta-1 and beta-2-adrenergic receptors with differential receptor reserves in rat C6 glioma cells. J Pharmacol Exp Ther. 1995 Mar;272(3):1088-94. PMID: 7891320. 17: Grudt TJ, Williams JT, Travagli RA. Inhibition by 5-hydroxytryptamine and noradrenaline in substantia gelatinosa of guinea-pig spinal trigeminal nucleus. J Physiol. 1995 May 15;485 ( Pt 1)(Pt 1):113-20. doi: 10.1113/jphysiol.1995.sp020716. PMID: 7658366; PMCID: PMC1157976. 18: Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res. 1994 May-Jun;14(3A):1215-20. PMID: 8074475. 19: Sempere T, Cedeño N, Urbina M, Lima L. 8-[3H]-hydroxy-2-(di-n- propylamino)tetralin binding sites in blood lymphocytes of rats and the modulation by mitogens and immobilization. J Neuroimmunol. 2003 May;138(1-2):8-16. doi: 10.1016/s0165-5728(03)00091-2. PMID: 12742647. 20: Ying SW, Zhang DX, Rusak B. Effects of serotonin agonists and melatonin on photic responses of hamster intergeniculate leaflet neurons. Brain Res. 1993 Nov 19;628(1-2):8-16. doi: 10.1016/0006-8993(93)90931-c. PMID: 8313174.